Loading…
Warby Parker Inc. sells eyewear products through its retail and e-commerce platform in the United States and Canada. The company offers eyeglasses and sunglasses; and single-vision, progressive, light-responsive, polarized, blue-light-filtering, tinted, non-prescription, and contact lenses. It also provides accessories, such as cases, pouches, lenses kit with anti-fog spray, travel cases, lenses cloth, anti-fog lens spray, and sun clip-ons through its stores, website, and mobile apps. In addition, the company offers eye exams and vision tests, as well as optical services. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $872M | $45M | $2M | $44M | 0.4% | 13.0% | - |
| 2024 | $771M | $16M | $-20M | $35M | -6.0% | 15.2% | - |
| 2023 | $670M | $-33M | $-63M | $7M | -20.9% | 12.0% | - |
| 2022 | $598M | $-79M | $-110M | $-50M | -38.5% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 598.11 | 669.76 | 771.32 | 871.90 |
| Cost Of Revenue | 257.05 | 304.54 | 344.48 | 401.33 |
| Gross Profit | 341.06 | 365.22 | 426.83 | 470.58 |
| Operating Expense | 452.26 | 437.22 | 456.95 | 475.92 |
| Operating Income | -111.20 | -72 | -30.11 | -5.34 |
| EBITDA | -79.34 | -33.44 | 15.75 | 44.94 |
| EBIT | -111.20 | -72 | -30.11 | -5.34 |
| Pretax Income | -109.90 | -62.76 | -19.52 | 3.04 |
| Tax Provision | 0.50 | 0.43 | 0.88 | 1.40 |
| Net Income | -110.39 | -63.20 | -20.39 | 1.64 |
| Net Income Common Stockholders | -110.39 | -63.20 | -20.39 | 1.64 |
| Total Expenses | 709.32 | 741.76 | 801.43 | 877.24 |
| Selling General And Administration | 452.26 | 437.22 | 456.95 | 475.92 |
| Normalized EBITDA | -79.34 | -33.44 | 15.75 | 44.94 |
| Normalized Income | -110.39 | -63.20 | -20.39 | 1.64 |
| Basic EPS | -0.96 | -0.54 | -0.17 | 0 |
| Diluted EPS | -0.96 | -0.54 | -0.17 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.21 | 0.21 |
| Net Income From Continuing Operation Net Minority Interest | -110.39 | -63.20 | -20.39 | 1.64 |
| Reconciled Depreciation | 31.86 | 38.55 | 45.87 | 50.28 |
| Reconciled Cost Of Revenue | 257.05 | 304.54 | 344.48 | 401.33 |
| Net Interest Income | 1.31 | 9.23 | 10.60 | 8.38 |
| Net Income From Continuing And Discontinued Operation | -110.39 | -63.20 | -20.39 | 1.64 |
| Total Operating Income As Reported | -111.20 | -72 | -30.11 | -5.34 |
| Diluted Average Shares | 114.94 | 117.39 | 120.39 | 0 |
| Basic Average Shares | 114.94 | 117.39 | 120.39 | 0 |
| Diluted NI Availto Com Stockholders | -110.39 | -63.20 | -20.39 | 1.64 |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -110.39 | -63.20 | -20.39 | 1.64 |
| Net Income Continuous Operations | -110.39 | -63.20 | -20.39 | 1.64 |
| Net Non Operating Interest Income Expense | 1.31 | 9.23 | 10.60 | 8.38 |
| Total Other Finance Cost | -1.31 | -9.23 | -10.60 | -8.38 |
| Operating Revenue | 598.11 | 669.76 | 771.32 | 871.90 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Warby Parker Inc.this co. | WRBY | $2.6B | 2147.00↑ premium | 7.15 | 0.4% | 56.61 |
| Haemonetics Corporation | HAE | $2.7B | 16.26 | 3.03 | 20.4% | 9.88 |
| Soleno Therapeutics, Inc. | SLNO | $2.7B | 135.33 | 6.13 | 4.6% | 145.68 |
| Kodiak Sciences Inc. | KOD | $2.7B | - | 17.11 | -146.1% | -11.78 |
| Tarsus Pharmaceuticals, Inc. | TARS | $2.6B |
| - |
| 7.52 |
| -19.3% |
| -32.50 |
| Immunome, Inc. | IMNM | $2.6B | - | 4.09 | -33.5% | -9.20 |
| Enliven Therapeutics, Inc. | ELVN | $2.6B | - | 5.48 | -22.6% | -17.36 |
| Vera Therapeutics, Inc. | VERA | $2.6B | - | 4.23 | -49.6% | -6.09 |
| Heartflow, Inc. | HTFL | $2.5B | - | 8.38 | -38.8% | -37.97 |
| Peer Median | - | 75.79 | 5.81 | -28.0% | -10.49 | |